SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the 8th Annual Needham Life Sciences Conference on Wednesday, June 10 at 2:30 p.m. Eastern Time in New York.
Dr. McMahon’s corporate presentation will include a discussion about the clinical development program for the Company’s lead product candidate, picoplatin.
A live audio webcast of the corporate overview will be available for 10 business days on the “Events” page of the “News & Events” section of the Company’s Web site at http://www.poniard.com.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company’s lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.
(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.
CONTACT: Susan Neath of Burns McClellan, +1-212-213-0006,
sneath@burnsmc.com; or Jani Bergan of WeissComm Partners, +1-415-946-1064,
jbergan@wcpglobal.com
Web site: http://www.poniard.com/
